Armata Pharmaceuticals Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

Armata PharmaceuticalsDer Gewinn des Unternehmens wird voraussichtlich um 52.2% pro Jahr sinken, während der Jahresumsatz voraussichtlich um 0.3% pro Jahr wachsen wird. Der Gewinn pro Aktie wird voraussichtlich zurückgehen.

Wichtige Informationen

-52.2%

Wachstumsrate der Gewinne

-42.0%

EPS-Wachstumsrate

Biotechs Gewinnwachstum	28.4%
Wachstumsrate der Einnahmen	0.3%
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Low
Zuletzt aktualisiert	14 Nov 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Gewinn- und Umsatzwachstumsprognosen

NYSEAM:ARMP - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2025	6	-69	N/A	N/A	1
12/31/2024	6	-35	N/A	N/A	1
9/30/2024	5	-41	-42	-38	N/A
6/30/2024	4	-67	-46	-39	N/A
3/31/2024	5	-80	-47	-40	N/A
12/31/2023	5	-69	-56	-47	N/A
9/30/2023	4	-60	-55	-50	N/A
6/30/2023	4	-37	-54	-50	N/A
3/31/2023	5	-43	-51	-47	N/A
12/31/2022	6	-37	-35	-32	N/A
9/30/2022	5	-33	-33	-31	N/A
6/30/2022	5	-29	-27	-25	N/A
3/31/2022	5	-26	-23	-22	N/A
12/31/2021	4	-23	-25	-24	N/A
9/30/2021	4	-24	-23	-21	N/A
6/30/2021	3	-24	-21	-20	N/A
3/31/2021	2	-23	-21	-20	N/A
12/31/2020	1	-22	-19	-18	N/A
9/30/2020	0	-20	-15	-15	N/A
6/30/2020	0	-21	-16	-15	N/A
3/31/2020	N/A	-21	-18	-17	N/A
12/31/2019	N/A	-19	-16	-16	N/A
9/30/2019	N/A	-16	-17	-16	N/A
6/30/2019	N/A	-12	-14	-14	N/A
3/31/2019	N/A	-11	-11	-10	N/A
12/31/2018	N/A	-17	-12	-11	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: ARMP wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: ARMP wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: ARMP wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: ARMPDie Einnahmen des Unternehmens (0.3% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt US (9% pro Jahr).

Hohe Wachstumseinnahmen: ARMPDie Einnahmen des Unternehmens (0.3% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von ARMP in 3 Jahren voraussichtlich hoch sein wird

Armata Pharmaceuticals Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Consensus revenue estimates decrease by 32%, EPS upgraded

Consensus EPS estimates fall by 43%

Consensus EPS estimates fall by 52%

Consensus revenue estimates decrease by 44%, EPS upgraded

Price target increased to US$8.00

Price target increased to US$8.00

Recent updates

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

Armata Pharmaceuticals Announces the Completion of Enrollment of its Phase 1b/2a diSArm Study Evaluating Intravenous AP-SA02 as a Potential Treatment for Staphylococcus aureus Bacteremia

New major risk - Revenue and earnings growth

Consensus revenue estimates decrease by 32%, EPS upgraded

Armata Pharmaceuticals Announces Principal Financial Officer Changes

Second quarter 2024 earnings released: EPS: US$0.25 (vs US$0.098 loss in 2Q 2023)

Armata Pharmaceuticals Receives $5.25 Million of Additional Non-Dilutive Grant Funding from the U.S. Department of Defense to Support Ongoing diSArm Clinical Trial of AP-SA02

Armata Pharmaceuticals, Inc. Announces Completion of Enrollment of Phase 2 Tailwind Study of Inhaled Ap-Pa02 in Non-Cystic Fibrosis Bronchiectasis Subjects with Chronic Pulmonary Pseudomonas Aeruginosa Infection

Consensus EPS estimates fall by 43%

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Insufficient new directors

Armata Pharmaceuticals, Inc., Annual General Meeting, Jun 12, 2024

New minor risk - Market cap size

Consensus EPS estimates fall by 52%

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Armata Pharmaceuticals Announces Presentation of Topline Data from SWARM-P.a. Clinical Study at the North American Cystic Fibrosis Conference

Armata Pharmaceuticals, Inc. Announces First Patient Dosed in the Phase 2A Portion of the Phase 1b/2a 'Disarm' Study of Ap-Sa02 in Adults with Bacteremia Due to Staphylococcus Aureus

Armata Pharmaceuticals, Inc. Announces CFO Changes

Consensus revenue estimates decrease by 44%, EPS upgraded

New minor risk - Revenue size

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

New major risk - Share price stability

Armata Pharmaceuticals, Inc. Announces Deborah L. Birx to Board of Directors

Armata Pharmaceuticals, Inc., Annual General Meeting, Aug 29, 2023

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Armata Pharmaceuticals, Inc. Announces Executive Changes

Full year 2022 earnings: EPS and revenues miss analyst expectations

Armata Pharmaceuticals, Inc. announced that it has received $30 million in funding from Innoviva Strategic Opportunities LLC

Armata Pharmaceuticals, Inc. announced that it has received $30 million in funding from Innoviva Strategic Opportunities LLC

Armata Pharmaceuticals Announces Completion of its Phase 1b/2a 'SWARM-P.a.' Study of Inhaled AP-PA02 in Cystic Fibrosis Subjects with Chronic Pulmonary Pseudomonas aeruginosa Infection

High number of new directors

Price target increased to US$8.00

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Armata Pharmaceuticals, Inc., Annual General Meeting, Nov 16, 2022

Price target increased to US$8.00

Consensus forecasts updated

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Armata Pharmaceuticals Announces Clearance of IND for Prosthetic Joint Infections

Armata Pharmaceuticals Announces First Patient Dosed in Phase 1b/2a 'diSArm' Study of AP-SA02 in Adults with Bacteremia Due to Staphylococcus Aureus

Consensus forecasts updated

High number of new directors

Armata Pharmaceuticals, Inc. announced that it has received $45 million in funding from Innoviva Strategic Opportunities LLC

Armata Pharmaceuticals, Inc. Announces CFO Changes

Consensus forecasts updated

Full year 2021 earnings: EPS misses analyst expectations

Armata Pharmaceuticals, Inc. Announces Clearance of Investigational New Drug Application to Initiate Phase 2 Clinical Trial of AP-PA02 in Non-Cystic Fibrosis Bronchiectasis

Price target increased to US$8.00

Armata Pharmaceuticals Provides Update on Pseudomonas Respiratory Programs

Third quarter 2021 earnings released: US$0.22 loss per share (vs US$0.31 loss in 3Q 2020)

Consensus forecasts updated

Price target increased to US$8.00

Consensus revenue estimates fall to US$666.7k

Armata Pharmaceuticals Inc. announced that it has received $20 million in funding from Innoviva, Inc.

Analysts update estimates

New 90-day high: US$5.07

New 90-day low: US$2.83

Earnings beat expectations, revenue disappoints

New 90-day high: US$3.94

Armata Pharmaceuticals Inc. Appoints Mina Pastagia as Vice President of Clinical Development

Armata Pharmaceuticals Announces Clearance of Investigational New Drug (IND) Application to Initiate Phase 1b/2a Clinical Trial of Lead Candidate AP-PA02 in Pseudomonas aeruginosa Infections

New 90-day low - US$3.26

Armata Pharmaceuticals Inc.(AMEX:ARMP) dropped from Russell Microcap Value Index

Gewinn- und Umsatzwachstumsprognosen

Analystenprognosen zum zukünftigen Wachstum

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Wachstumsunternehmen entdecken